Sigvotatug vedotin by Pfizer for Non-Small Cell Lung Cancer: Likelihood of Approval

Retrieved on: 2024-04-20 08:09:11

Tags for this article:

Click the tags to see associated articles and topics

Sigvotatug vedotin by Pfizer for Non-Small Cell Lung Cancer: Likelihood of Approval. View article details on hiswai:

Excerpt

Sigvotatug vedotin is under clinical development by Pfizer and currently in Phase III for Non-Small Cell Lung Cancer.

Article found on: www.pharmaceutical-technology.com